Jazz Pharmaceuticals Announces Third Quarter 2021 Financial Results And Raises Full Year Earnings Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/23/2026
- Nasdaq reaches record high close, AI stocks rally
- Meta AI agent triggers heavy selloff in banks, insurers, and travel stocks
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
Jazz Pharmaceuticals (JAZZ) PT Lowered to $202 at BMO Capital
November 10, 2021 6:33 AM ESTBMO Capital analyst Gary Nachman lowered the price target on Jazz Pharmaceuticals (NASDAQ: JAZZ) to $202.00 (from $205.00) while maintaining an Outperform rating.
The analyst commented, "3Q results beat with meaningfully lower opex driving significant EPS upside. Individual products were somewhat mixed, but we're seeing... More
Jazz Pharmaceuticals (JAZZ) Tops Q3 EPS by 89c
November 9, 2021 4:23 PM ESTJazz Pharmaceuticals (NASDAQ: JAZZ) reported Q3 EPS of $4.20, $0.89 better than the analyst estimate of $3.31. Revenue for the quarter came in at $838.1 million versus the consensus estimate of $832.52 million.
For earnings history and earnings-related data on Jazz Pharmaceuticals (JAZZ) click here.
... More